

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTADEG1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:46:43 ON 21 MAY 2008

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:47:00 ON 21 MAY 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8

DICTIONARY FILE UPDATES: 20 MAY 2008 HIGHEST RN 1021642-73-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-565048genA.str



```

chain nodes :
9 10 11 12 13 14 17
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
7-10 8-9 8-17 10-11 11-12 11-13 11-14
ring bonds :
1-2 1-7 2-3 2-8 3-4 4-5 5-6 5-8 6-7
exact/norm bonds :
1-2 1-7 2-3 2-8 3-4 4-5 5-6 5-8 6-7 11-12 11-13 11-14
exact bonds :
7-10 8-9 8-17 10-11

```

G1:Cb,Hy,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 17:CLASS

```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

CN1C(C)C(C)C(C)C1C(C)(O)G1

Structure attributes must be viewed using STN Express query preparation.

FULL SEARCH INITIATED 18:48:20 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 169 TO ITERATE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.82	179.03

The previous command name entered was not recognized by the system.


For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

```
=> s l3 and acetylcholine
      78230 ACETYLCHOLINE
      73 ACETYLCHOLINES
      78251 ACETYLCHOLINE
      (ACETYLCHOLINE OR ACETYLCHOLINES)
```

L4 3 L3 AND ACETYLCHOLINE

```
=> d l4 1-3 abs ibib hitstr
```

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
GI



AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH2, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; R3 = H, OH; X = physiol. acceptable anion], were prepared for treatment of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, 2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1,1-bis(3-methyl-2-thienyl)ethanol (preparation given) was treated with MeBr in tert-Bu Me ether to give 61% (3-endo)-3-[2-hydroxy-2,2-bis(3-methyl-2-thienyl)ethyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide.

ACCESSION NUMBER: 2007:146107 CAPLUS  
DOCUMENT NUMBER: 146:229203  
TITLE: Preparation of azoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists.  
INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 42pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016639	A2	20070208	WO 2006-US30153	20060802
WO 2007016639	A3	20070705		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,

US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-704579P P 20050802

OTHER SOURCE(S): MARPAT 146:229203

IT 924646-68-4P 924646-70-8P 924646-72-0P  
 924646-74-2P 924646-76-4P 924646-78-6P  
 924655-67-4P 924655-70-9P 924655-72-1P  
 924655-73-2P 924655-75-4P 924655-77-6P  
 924655-78-7P 924655-80-1P 924655-81-2P  
 924655-82-3P 924655-83-4P 924655-84-5P  
 924655-85-6P 924655-89-0P 924655-90-3P  
 924655-91-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(claimed compound; preparation of azoniabicyclooctanes as M3 muscarinic  
 acetylcholine receptor antagonists)

RN 924646-68-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methyl-2-  
 thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




● Br<sup>-</sup>

RN 924646-70-8 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methoxyphenyl)ethyl]-  
 8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924646-72-0 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(4-methyl-3-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)



Relative stereochemistry.



RN 924646-74-2 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(5-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)



Relative stereochemistry.



RN 924646-76-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-chloro-2-thienyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924646-78-6 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis[5-(difluoromethyl)-2-thienyl]-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.






RN 924655-67-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-fluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924655-70-9 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-fluoro-2-methylphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924655-72-1 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-3-thienylethyl)-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924655-73-2 CAPLUS


CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3,4-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924655-75-4 CAPLUS  
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3,5-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924655-77-6 CAPLUS  
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-fluoro-2-methoxyphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924655-78-7 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-fluoro-2-methylphenyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924655-80-1 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2,2-dicyclohexyl-2-hydroxyethyl)-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924655-81-2 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2,2-dicyclopentyl-2-hydroxyethyl)-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924655-82-3 CAPLUS


CN 8-Azoniabicyclo[3.2.1]octane, 3-[3-(2-fluorophenyl)-2-[(2-fluorophenyl)methyl]-2-hydroxypropyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924655-83-4 CAPLUS  
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-pyridinylethyl)-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924655-84-5 CAPLUS  
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(4-fluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924655-85-6 CAPLUS  
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(4-chlorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924655-89-0 CAPLUS  
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(3-chlorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924655-90-3 CAPLUS  
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(2,3-difluorophenyl)-2-hydroxyethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




RN 924655-91-4 CAPLUS  
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-(2,3-dichlorophenyl)-2-hydroxy-2-phenylethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
 GI



AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH<sub>2</sub>, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; X = pharmaceutically acceptable counterion], were prepared for treatment of



COPD, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, (endo)-3-[2,2-bis(3-hydroxyphenyl)ethenyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide was prepared from tri-Me phosphonoacetate, tropinone, MeI, and 3-methoxyphenylmagnesium bromide.

ACCESSION NUMBER: 2007:144089 CAPLUS  
DOCUMENT NUMBER: 146:229182  
TITLE: Preparation of 3-(arylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.3.1]octanes as M3 muscarinic acetylcholine receptor antagonists.  
INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo  
PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
SOURCE: PCT Int. Appl., 35pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016650	A2	20070208	WO 2006-US30218	20060802
WO 2007016650	A3	20070531		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2005-704578P P 20050802

OTHER SOURCE(S): MARPAT 146:229182

IT 924646-91-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylenedimethylazoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)

RN 924646-91-3 CAPLUS


CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(2-methoxyphenyl)ethyl]-8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.




IT 924646-68-4P 924646-70-8P 924646-72-0P  
 924646-74-2P 924646-76-4P 924646-78-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of arylenedimethylazoniabicyclooctanes as M3 muscarinic  
 acetylcholine receptor antagonists)  
 RN 924646-68-4 CAPLUS  
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methyl-2-  
 thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-70-8 CAPLUS  
 CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(3-methoxyphenyl)ethyl]-  
 8,8-dimethyl-, iodide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924646-72-0 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(4-methyl-3-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)



Relative stereochemistry.



RN 924646-74-2 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2,2-bis(5-methyl-2-thienyl)ethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)



Relative stereochemistry.



RN 924646-76-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis(5-chloro-2-thienyl)-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)


Relative stereochemistry.



RN 924646-78-6 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2,2-bis[5-(difluoromethyl)-2-thienyl]-2-hydroxyethyl]-8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



● Br<sup>-</sup>

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
 AB Muscarinic acetylcholine receptor antagonists, e.g.,  
 (3-endo)-3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-8-  
 azoniabicyclo[3.2.1]octane bromide and methods of using them are provided.  
 In addition a pharmaceutical composition for the treatment of muscarinic  
 acetylcholinereceptor-mediated diseases comprising the above compound is  
 disclosed.  
 ACCESSION NUMBER: 2005:99316 CAPLUS  
 DOCUMENT NUMBER: 142:183475  
 TITLE: Muscarinic acetylcholine receptor  
 antagonists  
 INVENTOR(S): Belmonte, Kristen E.; Busch-Petersen, Jakob; Laine,  
 Dramane; Palovich, Michael R.  
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK  
 SOURCE: PCT Int. Appl., 19 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009362	A2	20050203	WO 2004-US23041	20040716
WO 2005009362	A3	20050407		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004259238	A1	20050203	AU 2004-259238	20040716
CA 2532433	A1	20050203	CA 2004-2532433	20040716
EP 1648461	A2	20060426	EP 2004-778509	20040716
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1822839	A	20060823	CN 2004-80020652	20040716
BR 2004012537	A	20060919	BR 2004-12537	20040716

JP 2007525478	T	20070906	JP 2006-520387	20040716
IN 2006DN00077	A	20070824	IN 2006-DN77	20060104
MX 2006PA00663	A	20060330	MX 2006-PA663	20060117
US 20060178396	A1	20060810	US 2006-565048	20060117
NO 2006000777	A	20060411	NO 2006-777	20060217
PRIORITY APPLN. INFO.:			US 2003-487982P	P 20030717
			WO 2004-US23041	W 20040716

OTHER SOURCE(S): MARPAT 142:183475


IT 90114-71-9 102133-77-7 106655-98-5  
 106713-93-3 106954-22-7 834882-84-7  
 834882-85-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (muscarinic acetylcholine receptor antagonists)

RN 90114-71-9 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Br<sup>-</sup>

RN 102133-77-7 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-thienyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● Br<sup>-</sup>

RN 106655-98-5 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 106713-93-3 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyclohexyl-2-hydroxy-2-phenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 106954-22-7 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-pyridinyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 834882-84-7 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(3-cyclohexyl-2-hydroxy-2-phenylpropyl)-

8,8-dimethyl-, bromide (1:1), (3-endo)- (CA INDEX NAME)

Relative stereochemistry.



RN 834882-85-8 CAPLUS


CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, (3-endo)-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 805224-99-1

CMF C23 H30 N O


Relative stereochemistry.



CM 2

CRN 16722-51-3

CMF C7 H7 O3 S



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 18:50:45 ON 21 MAY 2008